We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+3.33%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.83B
AUM Growth
-$147M
Cap. Flow
+$37.6M
Cap. Flow %
0.48%
Top 10 Hldgs %
76.26%
Holding
100
New
11
Increased
18
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$125M
2
INSM icon
Insmed
INSM
+$125M
3
ALKS icon
Alkermes
ALKS
+$103M
4
BCYC
Bicycle Therapeutics
BCYC
+$101M
5
ALMS
Alumis Inc
ALMS
+$20.8M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$308M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$55.5M
3
ROIV icon
Roivant Sciences
ROIV
+$50.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$38.2M
5
AKRO
Akero Therapeutics
AKRO
+$34.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADAP
76
DELISTED
Adaptimmune Therapeutics
ADAP
$2.28M 0.03%
2,343,695
-8,443,327
-78% -$9.27M
MRSN
77
DELISTED
Mersana Therapeutics
MRSN
$2.18M 0.03%
43,445
– –
IPSC icon
78
Century Therapeutics
IPSC
$375M
$2.03M 0.03%
797,460
– –
NAMS icon
79
NewAmsterdam Pharma
NAMS
$3.33B
$1.86M 0.02%
96,827
– –
SAGE
80
DELISTED
Sage Therapeutics
SAGE
$1.86M 0.02%
171,026
-236,191
-58% -$3.03M
VTVT icon
81
vTv Therapeutics
VTVT
$132M
$1.72M 0.02%
97,314
– –
CMPX icon
82
Compass Therapeutics
CMPX
$432M
$1.56M 0.02%
1,557,630
– –
TARA icon
83
Protara Therapeutics
TARA
$228M
$1.12M 0.01%
536,832
+337,161
+169% +$986K
JBIO
84
Jade Biosciences
JBIO
$1.36B
$1.04M 0.01%
17,970
-30,045
-63% -$19.9M
PFE icon
85
Pfizer
PFE
$160B
$979K 0.01%
35,000
– –
ACHL
86
DELISTED
Achilles Therapeutics
ACHL
$904K 0.01%
1,108,767
-100,008
-8% -$87.9K
ALGS icon
87
Aligos Therapeutics
ALGS
$41.7M
$727K 0.01%
83,056
– –
PMVP icon
88
PMV Pharmaceuticals
PMVP
$71.1M
$522K 0.01%
322,024
– –
BCRX icon
89
BioCryst Pharmaceuticals
BCRX
$2.44B
$468K 0.01%
75,778
-10,050,398
-99% -$55.5M
ACRV icon
90
Acrivon Therapeutics
ACRV
$94.7M
$307K ﹤0.01%
52,885
– –
FHTX icon
91
Foghorn Therapeutics
FHTX
$420M
$259K ﹤0.01%
45,027
– –
TYRA icon
92
Tyra Biosciences
TYRA
$1.55B
$170K ﹤0.01%
10,607
– –
SRZNW
93
DELISTED
Surrozen Inc Warrant
SRZNW
$13.8K ﹤0.01%
833,333
– –
CABA icon
94
Cabaletta Bio
CABA
$531M
– –
-13,331
Closed -$227K
CATX icon
95
Perspective Therapeutics
CATX
$377M
– –
-14,979
Closed -$178K
FDMT icon
96
4D Molecular Therapeutics
FDMT
$875M
– –
-100,000
Closed -$3.19M
MURA
97
DELISTED
Mural Oncology
MURA
– –
-222,503
Closed -$1.09M
ALPN
98
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-81,578
Closed -$3.23M
1 2 3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2024 Portfolio in Review

As of Q2 2024, Julian Baker held 100 positions worth $7.83B, down 1.8% from $7.97B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Julian Baker's Q2 2024 filing shows 11 new, 18 increased, 11 reduced and 5 closed positions. Its largest new stake was Summit Therapeutics: 23,222,222 shares worth $181M. The largest sale was Incyte, an estimated $308M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2024 buy was Summit Therapeutics: 23,222,222 shares worth $181M.
  • Julian Baker added most to Insmed in Q2 2024, an estimated $125M increase.
  • Julian Baker's biggest Q2 2024 reduction was Incyte, cutting an estimated $308M.
  • Julian Baker fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $3.23M.
  • Julian Baker's ten largest holdings make up 76% of its $7.83B portfolio in Q2 2024.
  • Julian Baker opened 11 new positions and closed 5 in Q2 2024.
  • Julian Baker's portfolio value fell 1.8% quarter-over-quarter to $7.83B.

Based on Baker Bros. Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.